Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly

Dwyer, Michael G.; Zivadinov, Robert; Marković-Pleše, Silva; Bergsland, Niels; Heininen-Brown, Mari; Carl, Ellen; Kennedy, Cheryl; Weinstock‐Guttman, Bianca; Hayward, Brooke; Dangond, Fernando

doi:10.1016/j.jneuroim.2015.03.002

Cited by 4 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Iron has previously been measured using R 2 *, which is known to suffer from blooming artifacts and to depend on imaging parameters. Recently, QSM has been demonstrated as a more sensitive detector of iron accumulation in the substantia nigra pars compacta as compared with R 2 * . Therefore, QSM is the best currently‐available biomarker for monitoring of iron‐chelation therapy.…”

Section: Qsm‐guided Medical Managementmentioning

confidence: 99%

“…QSM identifies increased iron in the substantia nigra and red nucleus in the earliest stages of disease, suggesting that QSM could potentially serve as an early diagnostic tool (see Fig. ) . QSM can also assess for lateral asymmetries and spatial differences in iron deposition within the substantia nigra .…”

Section: Qsm For Diagnosing Neurodegenerative Diseasesmentioning

confidence: 99%

“…While QSM has been continuously improving like many MRI techniques, the basic Bayesian approach with the Gauss–Newton solver for a cost function consisting of a data fidelity term of proper noise weighting and a regularization term penalizing streaking artifacts can provide reasonably accurate and robust brain mapping , and several groups have independently demonstrated that this Bayesian QSM is highly reproducible across field strengths, MRI manufacturers, and hospital sites . There are many clinical studies evaluating diseases involving iron , calcification and myelin . Mapping iron – the dominant susceptibility source in the brain – has many important clinical applications in diagnosing, monitoring, and treating diseases of the central nervous system.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The clinical utility of QSM: disease diagnosis, medical management, and surgical planning

Eskreis‐Winkler

Zhang

et al. 2016

NMR in Biomedicine

View full text Add to dashboard Cite

Quantitative susceptibility mapping (QSM) is an MR technique that depicts and quantifies magnetic susceptibility sources. Mapping iron, the dominant susceptibility source in the brain, has many important clinical applications. Herein, we review QSM applications in the diagnosis, medical management, and surgical treatment of disease. To assist in early disease diagnosis, QSM can identify elevated iron levels in the motor cortex of amyotrophic lateral sclerosis patients, in the substantia nigra of Parkinson's disease (PD) patients, in the globus pallidus, putamen, and caudate of Huntington's disease patients, and in the basal ganglia of Wilson's disease patients. Additionally, QSM can distinguish between hemorrhage and calcification, which could prove useful in tumor subclassification, and can measure microbleeds in traumatic brain injury patients. In guiding medical management, QSM can be used to monitor iron chelation therapy in PD patients, to monitor smoldering inflammation of multiple sclerosis (MS) lesions after the blood-brain barrier (BBB) seals, to monitor active inflammation of MS lesions before the BBB seals without using gadolinium, and to monitor hematoma volume in intracerebral hemorrhage. QSM can also guide neurosurgical treatment. Neurosurgeons require accurate depiction of the subthalamic nucleus, a tiny deep gray matter nucleus, prior to inserting deep brain stimulation electrodes into the brains of PD patients. QSM is arguably the best imaging tool for depiction of the subthalamic nucleus. Finally, we discuss future directions, including bone QSM, cardiac QSM, and using QSM to map cerebral metabolic rate of oxygen. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Qsm‐guided Medical Managementmentioning

confidence: 99%

Section: Qsm For Diagnosing Neurodegenerative Diseasesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical utility of QSM: disease diagnosis, medical management, and surgical planning

Eskreis‐Winkler

Zhang

et al. 2016

NMR in Biomedicine

View full text Add to dashboard Cite

show abstract

“…Відомо, що деякі препарати можуть знижувати рівень ЛДГ, однак такі зміни за РС є нетиповими й не узгоджуються з висновками інших досліджень . Оскільки низький рівень ЛДГ корелює з ризиком розвитку депресивних станів (Dwyer et al, 2015), що також може сприяти прогресуванню РС і його супутніх ускладнень, то наші результати мають бути перевірені на більш широкій вибірці пацієнтів з урахуванням можливих порушень когнітивних функцій, виявів депресивних станів, схильності до суїцидальної поведінки тощо.…”

Section: дискусія і висновкиunclassified

Blood Biochemical Parameters in Patients With Multiple Sclerosis Who Had Sars-Cov-2 Infection

Halenova,

Kalashnikova,

Karbovskyy

et al. 2023

BTSNUKSB

View full text Add to dashboard Cite

B a c k g r o u n d. Currently, multiple sclerosis (MS) is an important medical and social problem. There are already more than 2.8 million people with MS worldwide, and due to the lack of effective methods of treatment and prevention, the number of patients is increasing constantly. Therefore, the search for new ways and approaches aimed towards stabilizing the patient's condition is a priority task of modern neurobiology. It is also important to identify triggers that can lead to accelerating the rate of disease progression. Since MS is an immune-mediated disorder, we hypothesized that concomitant diseases of infectious etiology, via the activation of an inflammatory reactions cascade, can lead to a worsening of the MS patient's condition. However, the final answer to the question of whether acute viral infections affect the condition of patients with MS has not been obtained yet. In the context of the epidemiological situation that has developed in recent years, due to the spread of the SARS-CoV-2 coronavirus infection, it is interesting to study the possible negative consequences of COVID-19 in people suffering from MS. The aim of the study was to analyze the general biochemical status of patients with MS who had or did not have a confirmed history of COVID-19. M e t h o d s. A total of 271 participants were enrolled in this study, including 97 MS patients and 30 healthy volunteers who matched for age and sex. Patients with MS were divided into two groups: group I (n= 56; 36 women and 20 men, average age: 41.3±5.5, disease duration: 4.4±1.5 years) – patients with MS who did not have confirmed history of COVID-19 and group II (n= 41; 27 women and 14 men, average age: 40.2±5.6, disease duration: 4.6±1.3 years) – patients with MS, who had a laboratory-verified diagnosis of COVID-19 in the past 4-7 months. Blood serum samples of patients and healthy donors were obtained from the University Clinic of O.O. Bogomolets National Medical University, Kyiv, Ukraine. All patients were diagnosed with MS according to the 2017 McDonald criteria. R e s u l t s. It was established that both groups of MS patients had similar changes in blood biochemical parameters compared to the healthy indicators: a decrease in creatinine and uric acid concentrations; decrease in the levels of particular lipid fractions, namely VLDL and TAG; decrease in the activities of AP and LDH; increase in C-reactive protein concentration. The only significant differences between groups I and II were noted due to multidirectional changes in serum ferritin concentration and an increase in the level of amylase activity in the blood serum of patients with MS in post- COVID period. C o n c l u s i o n s. The absence of statistically significant differences between the blood biochemical parameters in patients with MS who had or did not have confirmed history of COVID-19 indicates the absence of a relationship between SARS-CoV-2 infection and changes of particular studied parameters. Among the results obtained, the multidirectional changes in ferritin concentration in MS patients before and after COVID-19 could be of great interest to further research.

show abstract

Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review

De Lury,

Bisulca,

Lee

et al. 2023

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly

Cited by 4 publications

References 38 publications

The clinical utility of QSM: disease diagnosis, medical management, and surgical planning

The clinical utility of QSM: disease diagnosis, medical management, and surgical planning

Blood Biochemical Parameters in Patients With Multiple Sclerosis Who Had Sars-Cov-2 Infection

Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review

Contact Info

Product

Resources

About